396 Results

People

  1. Kris
    Kris
  2. Riely
    Riely
  3. Pao
    Pao
  4. Ladanyi
    Ladanyi
  5. O'Reilly
    O'Reilly
  6. Miller
    Miller
  7. Yu
    Yu
  8. Abou-Alfa
    Abou-Alfa
  9. Zakowski
    Zakowski
  10. Lacouture
    Lacouture

Groups

  1. Department of Medicine (237)
  2. Solid Tumor Oncology Division (203)
  3. Thoracic Oncology (97)
  4. GSK Faculty (87)
  5. Gastrointestinal Oncology Service (74)
  6. Tow Center for Developmental Oncology (TCDO) (70)
  7. Human Oncology and Pathogenesis Program (65)
  8. Department of Pathology and Laboratory Medicine (64)
  9. Center for Pancreatic Cancer Research (43)
  10. Surgery (43)
  1. "erlotinib"
Formats
  1. Journal Article (362)
  2. Review (16)
  3. Meeting Abstract (7)
  4. Conference Paper (4)
  5. Book Section (2)
  6. Editorial (2)
  7. Guidelines (2)
  8. Correspondence (1)
Groups
  1. Department of Medicine (237)
  2. Solid Tumor Oncology Division (203)
  3. Thoracic Oncology (97)
  4. GSK Faculty (87)
  5. Gastrointestinal Oncology Service (74)
  6. Tow Center for Developmental Oncology (TCDO) (70)

More Groups

People
  1. Mark Kris (53)
  2. Gregory Riely (51)
  3. Vincent Miller (45)
  4. William Pao (42)
  5. Marc Ladanyi (41)
  6. Eileen O'Reilly (28)

More People

Years
  1. 2025 (2)
  2. 2024 (9)
  3. 2023 (5)
  4. 2022 (7)
  5. 2021 (6)
  6. 2020 (7)

More Years

Publications
  1. Clinical Cancer Research (35)
  2. Journal of Thoracic Oncology (33)
  3. Journal of Clinical Oncology (23)
  4. Cancer (12)
  5. Journal of the National Comprehensive Cancer Network (11)
  6. Supportive Care in Cancer (8)

More Publications

Publishers
  1. Elsevier Inc. (77)
  2. American Association for Cancer Research (45)
  3. American Society of Clinical Oncology (26)
  4. Oxford University Press (21)
  5. Springer (21)
  6. Wiley Blackwell (21)

More Publishers

Results (396)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeted therapies for esophageal cancer
    Journal Article

    Tew, W. P.; Kelsen, D. P.; Ilson, D. H.
    The Oncologist (2005)

    Fulltext@MSK | Save
  • Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology
    Journal Article

    Tempero, M. A.; Behrman, S.; Ben-Josef, E.; Benson, A. B. 3rd; Cameron, J. L.; Casper, E. S.; Hoffman, J. P.; Karl, R. C.; Kim, P.; Koh, W. J.; more...
    Journal of the National Comprehensive Cancer Network (2005)

    Fulltext@MSK | Save
  • New agents and new formulations for the treatment of ovarian cancer
    Journal Article

    Sabbatini, P.
    Clinical Advances in Hematology & Oncology (2005)

    Fulltext@MSK | Save
  • Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: Biology, clinical results and future development
    Journal Article

    Rini, B. I.; Sosman, J. A.; Motzer, R. J.
    BJU International (2005)

    Fulltext@MSK | Save
  • Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: Is timing important?
    Journal Article

    Riely, G. J.; Pao, W.
    Cancer Biology and Therapy (2005)

    Fulltext@MSK | Save
  • HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum
    Journal Article

    Perez-Soler, R.; Delord, J. P.; Halpern, A.; Kelly, K.; Krueger, J.; Sureda, B. M.; Von Pawel, J.; Temel, J.; Siena, S.; Souliè€res, D.; more...
    The Oncologist (2005)

    Fulltext@MSK | Save
  • KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
    Journal Article

    Pao, W.; Wang, T. Y.; Riely, G. J.; Miller, V. A.; Pan, Q.; Ladanyi, M.; Zakowski, M. F.; Heelan, R. T.; Kris, M. G.; Varmus, H. E.
    PLos Medicine (2005)

    Fulltext@MSK | Save
  • Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions
    Journal Article

    Pao, W.; Miller, V. A.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    Journal Article

    Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H.
    PLos Medicine (2005)

    Fulltext@MSK | Save
  • Erlotinib in lung cancer - Reply
    Journal Article

    Pao, W.; Ladanyi, M.; Miller, V. A.
    New England Journal of Medicine (2005)

    Fulltext@MSK | Save